Your Support & How It Was Used Fiscal Year 2024 Impact Report(July 1, 2023 – June 30, 2024) Get the 2024 Impact Report Now Download Now Financial Scale Investing in Cancer Immunotherapy Research CRI’s research is guided by our renowned Scientific Advisory Council, led by 2018 Nobel laureate James P. Allison, PhD. CRI scientists around the world are leading the charge to fuel the next wave of immunotherapy treatments. $22.8M Invested in research 64 Grants 42 Institutions 7 Countries Take a glimpse at CRI’s inaugural Bioinformatics Bootcamp, created to equip immunologists with essential data science skills. Forty-four CRI Postdoctoral Fellows gained hands-on training to leverage data and advance cancer immunotherapy research. “Immunotherapy is one of the most significant advances for treating cancer in the modern era. The field is what it is today because CRI continues to be laser-focused on breakthrough immunotherapy research.” James P. Allison, PhDThe University of Texas MD Anderson Cancer CenterCRI Scientific Advisory Council Director 2018 Nobel Laureate Make your impact on cancer research DONATE NOW 32 Postdoctoral Fellowships* 7 CLIP Awards (Clinic and Laboratory Integration Program) 5 Stars (Scientists Taking Risks) 5 Technology Impact Awards 3 Clinical Innovator Trials 1 Bioinformatics Bootcamp *Includes 3 Fellowships to Promote Racial Diversity and 4 Immuno-Informatics Fellowships Program Scale Building a Community of Scientific Talent CRI is committed to building a community of scientific talent by supporting outstanding researchers across diverse disciplines. Our investment in fellowships, awards, and integration programs ensures that scientists are empowered to take risks, innovate, and bridge the gap between research and clinical practice. Discover the latest in our Fiscal Year 2024 Impact Video Series, featuring CRI Postdoctoral Fellow Dr. Chiara Falcomatà’s pioneering research on pancreatic cancer’s evasion of the immune system. CRI’s 71 years of investment in research are transforming treatment possibilities, with 45% of newly diagnosed cancer patients now eligible for immunotherapy. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Bootcamp Video Thumbnail Gavin Peter Dunn, MD, PhDMassachusetts General Hospital CRI Lloyd J. Old STAR Gavin Peter Dunn, MD, PhD, is a neurosurgeon-scientist studying how the immune system responds to brain tumors, a largely uncharted area of cancer research. While immunotherapies have revolutionized treatment for certain cancers, they have yet to make a significant impact on brain tumors, partly due to the complex biology and unique barriers present in the brain. Recently, Dr. Dunn made a groundbreaking discovery, identifying a subset of immune cells that behave differently in brain tumors—a finding that could be leveraged for developing new therapies. Chiara Falcomatà, PhD Icahn School of Medicine at Mount Sinai CRI Postdoctoral Fellow Pancreatic cancer is one of the most aggressive and deadly forms of cancer, with a grim prognosis and few effective treatment options. Its tumor environment cleverly evades the body’s immune response, rendering many therapies ineffective—a challenge scientists are still working to fully understand. Chiara Falcomatà, PhD, is at the forefront of research aimed at uncovering how pancreatic cancer cells outmaneuver the immune system. CRI Lloyd J. Old STAR Gavin Peter Dunn, MD, PhD, a neurosurgeon-scientist, is studying how the immune system responds to brain tumors. With the support and funding from CRI, Dr. Dunn is tackling this largely unexplored area of cancer research from multiple angles, paving the way for potential new treatments. Our Mission SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers. Human Scale Bringing the Promise of Immunotherapy to More Patients CRI is committed to bringing the promise of immunotherapy to more patients worldwide. With 29 cancers now treatable with immunotherapy, new FDA approvals, and nearly half of all newly diagnosed patients eligible, CRI’s impact is transforming lives on a global scale. 29 Cancers now treatable with immunotherapy 45% Of newly diagnosed patients are eligible for immunotherapy 13 New FDA approvals Karen was diagnosed with stage 1 triple-negative breast cancer. After undergoing traditional treatments, her cancer returned in 2017 as metastatic, accompanied by a devastating prognosis of just 18 to 24 months to live. Refusing to accept this, Karen sought information about immunotherapy and other treatment options and discovered CRI. She found a phase 1 clinical trial that offered new hope. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Bootcamp Video Thumbnail Trust and Transparency Investing in Impact In FY2024, 83% of CRI’s total operating expenses went directly to supporting research and education programs. CRI consistently receives exemplary marks from watchdog groups, including an A Rating from CharityWatch, Platinum Seal of Transparency from GuideStar, and a 100% Four Stars rating from Charity Navigator. CRI is a proud member of the BBB Wise Giving Alliance, meeting all 20 standards of charity accountability. Make your impact on cancer research DONATE NOW Ranked among the top 5% of U.S. rated charities
